Focus: Iovance is a clinical-stage biotechnology company specializing in adoptive cell therapy, primarily leveraging tumor-infiltrating lymphocytes (TIL) for solid tumors and hematologic malignancies. The company operates as a mid-cap biotech with a focused pipeline concentrated in oncology.
Profile data last refreshed 13h ago · AI intelligence enriched 1w ago
Hot — 138 jobs added in 30d
Net +114 (138 new, 24 removed). Aggressive expansion phase.
Iovance offers high-growth potential in a cutting-edge modality with solid hiring momentum, but pre-revenue status and manufacturing complexity warrant careful assessment of company burn rate and funding runway.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Iovance Biotherapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Iovance Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo